Saturday 17 October 2026
Export TLSI’s income statement to Excel — free account
TriSalus Life Sciences, Inc.
TLSI Healthcare Medical Devices
TriSalus Life Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $45.2 million, up 53.4% from fiscal 2024. In the quarter to June 2026, revenue grew 1.73%, EPS grew 40.7%, free cash flow fell 41.3% and total debt rose 2.45%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
3.63
0.27
−6.92%
Follow TLSI
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '17 | |
|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Piotroski F-Score |
3 | 4 | — | — | — | — | — |
Altman Z-Score |
(11.34) | (18.03) | (19.53) | (17.58) | — | — | — |
P/S ratio |
5.86 | 4.31 | 4.19 | 0.00 | — | — | — |
Altman Z″-Score (non-manufacturers) |
(32.29) | (45.84) | (46.85) | (44.20) | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Beneish M-Score |
(5.08) | (0.34) | (3.28) | — | — | — | — |
P/Operating CF |
(106.49) | (22.24) | (8.45) | (0.37) | — | — | — |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
EV/Sales |
6.14 | 4.78 | 3.64 | 0.00 | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.11 | — | — | — |
EV/Operating CF |
(15.40) | (3.45) | (1.33) | 0.12 | — | — | — |
EV/FCF |
(14.16) | (3.36) | (1.30) | 0.12 | — | — | — |
Quick Ratio |
2.35 | 1.33 | 1.04 | 0.34 | 0.13 | 12.94 | — |
Current Ratio |
2.80 | 2.02 | 1.42 | 0.53 | 0.33 | 19.46 | — |
Net Debt/EBITDA |
(0.50) | (0.39) | 0.22 | 0.22 | (0.11) | 12.30 | — |
Debt/Assets |
93.53% | 92.13% | 0.00% | 6.10% | 0.22% | 0.00% | 0.00% |
Debt/Equity |
(0.98) | (0.85) | 0.00 | (0.01) | (0.03) | 0.00 | — |
Asset Turnover |
1.52 | 1.21 | 0.79 | 0.09 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.26 | 1.23 | 0.80 | 0.65 | (0.36) | 0.95 | — |
Capex/Depreciation |
(0.50) | (0.25) | (1.64) | (1.97) | — | — | — |
Interest Coverage |
(4.86) | (11.70) | (3,404.69) | (36,439.00) | (47.51) | (32.88) | — |
| 233.25% | 125.50% | 62.54% | 51.82% | (24.96%) | (0.60%) | — | |
| (235.03%) | (136.85%) | (273.01%) | (36.71%) | 1.90% | (0.56%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(309.01%) | (274.43%) | (769.44%) | 387.36% | (443.18%) | (37.34%) | — |
Average Days of Receivables |
53.01 | 63.09 | 70.08 | 45.84 | — | — | — |
Research and Development Expense of Revenue |
33.14% | 60.10% | 161.17% | 172.27% | — | — | — |
Selling, General and Administrative Expense of Revenue |
111.11% | 148.84% | 219.04% | 203.43% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
20.22% | 18.49% | 7.57% | 2.97% | — | — | — |
Graham Net Nets |
(0.14) | (0.23) | (0.40) | (58.13) | — | — | — |
Graham Number |
6.07 | 5.53 | 46.62 | 1,395.74 | — | — | — |
Earnings Yield |
(26.22%) | (26.55%) | (406.46%) | (1,514.59%) | — | — | — |
Free Cash Flow Yield |
(7.40%) | (33.04%) | (66.96%) | (1,058.19%) | — | — | — |
Revenue per Share |
1.19 | 1.16 | 1.97 | 39.99 | 0.00 | 0.00 | — |
Operating CF per Share |
(0.48) | (1.61) | (5.38) | (104.24) | (0.28) | (0.11) | — |
Capex per Share |
(0.02) | (0.01) | (0.12) | (2.54) | 0.00 | 0.00 | — |
Free Cash Flow per Share |
(0.50) | (1.63) | (5.50) | (106.77) | (0.28) | (0.11) | — |
Cash per Share |
0.54 | 0.34 | 1.25 | 30.37 | 0.03 | 0.21 | — |
Shareholders Equity per Share |
(0.89) | (1.02) | (2.88) | (568.81) | (2.67) | (3.40) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
(0.89) | (1.02) | (2.88) | (568.81) | (2.67) | (3.40) | — |
Free Cash Flow |
(18.85) | (41.19) | (51.70) | (33.10) | (1.74) | (0.68) | — |
Working Capital |
20.75 | 10.44 | 6.18 | (15.14) | (1.08) | 1.91 | — |
Capital Expenditures |
(0.84) | (0.34) | (1.12) | (0.79) | — | — | — |
Net Current Asset Value |
(36.95) | (29.20) | (30.80) | (181.11) | (266.72) | (271.49) | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.11 | — | — | — |
Capex to Sales |
0.02 | 0.01 | 0.06 | 0.06 | — | — | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Other line items | |||||||
Depreciation/Fixed assets |
0.93 | 0.81 | 0.33 | 0.18 | — | — | — |
Cash ROIC |
(96.06%) | (873.55%) | 338.17% | 19.99% | 10.88% | 3.36% | — |
Accounts Receivable Turnover |
7.75 | 6.81 | 7.24 | 0.00 | — | — | — |
Accounts Payable Turnover |
2.64 | 1.45 | 0.62 | 0.75 | — | — | — |
Inventory Turnover |
1.96 | 1.24 | 1.30 | 0.00 | — | — | — |
Average Days of Payables |
157.32 | 202.29 | 475.13 | 799.67 | 0.00 | — | — |
Days of Inventory on Hand |
161.25 | 360.11 | 356.59 | 237.78 | — | — | — |
Average Receivables |
5.82 | 4.32 | 2.56 | — | — | — | — |
Average Payables |
2.64 | 2.83 | 4.17 | 3.00 | — | — | — |
Average Inventory |
3.56 | 3.30 | 2.01 | — | — | — | — |
Average Assets |
29.65 | 24.28 | 23.30 | 136.26 | 251.27 | 126.01 | — |
Average Common Equity |
(29.88) | (26.48) | (101.70) | (96.52) | (19.10) | 119.14 | — |
Columns are period end dates